{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T17:27:29Z","timestamp":1770830849684,"version":"3.50.1"},"reference-count":25,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Global measles vaccine coverage has stagnated at approximately 85% for over a decade. By simplifying vaccine logistics and administration, the measles and rubella microarray patch (MR-MAP) may improve coverage. Clinical trials have demonstrated similar safety and immunogenicity in 9-month-old infants for MR-MAPs compared with syringe-and-needle vaccination. To aid commercialization, we present estimates of MR-MAP demand. We created a spreadsheet-based tool to estimate demand for MR-MAPs using data from 180 WHO countries during 2000\u20132016. Five immunization scenarios were analyzed: (1a) Supplementary Immunization Activities (SIAs) in Gavi, the Vaccine Alliance (Gavi)-eligible countries and (1b) WHO countries where preventive SIAs are routinely conducted; (2) SIAs and outbreak response immunization in all WHO countries; (3) routine immunization (RI) and SIAs in six high-burden measles countries (the Democratic Republic of the Congo, Ethiopia, India, Indonesia, Nigeria, and Pakistan); (4) RI and SIAs in six high-burden countries and Gavi-eligible countries; and (5) hard-to-reach populations. MR-MAP demand varied greatly across scenarios. Forecasts for 2025\u20132034 estimate from 137 million doses in hard-to-reach populations (scenario 5) to 2.587 billion doses for RI and SIAs in six high-burden countries and Gavi-eligible countries (scenario 4). When policymakers and manufacturers assess MR-MAP demand, they may consider multiple scenarios to allow for a complete consideration of potential markets and public health needs.<\/jats:p>","DOI":"10.3390\/vaccines12091083","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T03:36:38Z","timestamp":1727062598000},"page":"1083","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Estimates of Potential Demand for Measles and Rubella Microarray Patches"],"prefix":"10.3390","volume":"12","author":[{"given":"Lidia K.","family":"Kayembe","sequence":"first","affiliation":[{"name":"The U.S. Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9675-6133","authenticated-orcid":false,"given":"Leah S.","family":"Fischer","sequence":"additional","affiliation":[{"name":"The U.S. Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4209-305X","authenticated-orcid":false,"given":"Bishwa B.","family":"Adhikari","sequence":"additional","affiliation":[{"name":"The U.S. Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4626-344X","authenticated-orcid":false,"given":"Jennifer K.","family":"Knapp","sequence":"additional","affiliation":[{"name":"The U.S. Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emily B.","family":"Khan","sequence":"additional","affiliation":[{"name":"The U.S. Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2727-2287","authenticated-orcid":false,"given":"Bradford R.","family":"Greening","sequence":"additional","affiliation":[{"name":"The U.S. Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Papania","sequence":"additional","affiliation":[{"name":"The U.S. Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7250-0472","authenticated-orcid":false,"given":"Martin I.","family":"Meltzer","sequence":"additional","affiliation":[{"name":"The U.S. Centers for Disease Control and Prevention, 1600 Clifton Rd NE, Atlanta, GA 30329, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"key":"ref_1","unstructured":"Measles & Rubella Initiative (2024, February 12). The Problem. Available online: https:\/\/measlesrubellainitiative.org\/learn\/the-problem\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.15585\/mmwr.mm7246a3","article-title":"Progress Toward Regional Measles Elimination\u2014Worldwide, 2000\u20132022","volume":"72","author":"Minta","year":"2023","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.15585\/mmwr.mm7308a2","article-title":"Progress Toward Rubella and Congenital Rubella Syndrome Elimination\u2014Worldwide, 2012\u20132022","volume":"73","author":"Ou","year":"2024","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_4","unstructured":"United Nations International Children\u2019s Emergency Fund (UNICEF) (2024, September 05). More than 117 Million Children at Risk of Missing out on Measles Vaccines, as COVID-19 Surges. Available online: https:\/\/www.unicef.org\/press-releases\/more-117-million-children-risk-missing-out-measles-vaccines-covid-19-surges."},{"key":"ref_5","unstructured":"World Health Organization (2017). Measles vaccines: WHO position paper\u2014April 2017. Wkly. Epidemiol. Record, 92, 205\u2013228."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.addr.2021.01.022","article-title":"Microarray patches enable the development of skin-targeted vaccines against COVID-19","volume":"171","author":"Korkmaz","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_7","unstructured":"VAXXAS (2024, February 12). Technology Platform. Available online: https:\/\/www.vaxxas.com\/technology-platform\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/S0140-6736(24)00532-4","article-title":"A measles and rubella vaccine microneedle patch in The Gambia: A phase 1\/2, double-blind, double-dummy, randomised, active-controlled, age de-escalation trial","volume":"403","author":"Adigweme","year":"2024","journal-title":"Lancet"},{"key":"ref_9","unstructured":"World Health Organization, and UNICEF (2024, February 12). Measles-Rubella Microarray Patch (MR\u2013MAP) Target Product Profile. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/330394\/9789240000209-eng.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Ko, M., Malvolti, S., Cherian, T., Mantel, C., Biellik, R., Jarrahian, C., Menozzi-Arnaud, M., Amori, J.-P., Christiansen, H., and Papania, M.J. (2023). Estimating the future global dose demand for measles-rubella microarray patches. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.1037157"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Nkenyi, R., Pak, G.D., Tonga, C., Chon, Y., Park, S.E., and Kang, S. (2022). A retrospective review of vaccine wastage and associated risk factors in the Littoral region of Cameroon during 2016\u20132017. BMC Public Health, 22.","DOI":"10.1186\/s12889-022-14328-w"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1016\/j.vaccine.2023.05.033","article-title":"Vaccine wastage in Ghana, Mozambique, and Pakistan: An assessment of wastage rates for four vaccines and the context, causes, drivers, and knowledge, attitudes and practices for vaccine wastage","volume":"41","author":"Mvundura","year":"2023","journal-title":"Vaccine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.11604\/pamj.2021.40.114.28373","article-title":"Assessment of vaccine wastage in South Sudan","volume":"40","author":"Bol","year":"2021","journal-title":"Pan Afr. Med. J."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Dadari, I., Ropiti, L., Patson, A., Okia, P., Narasia, J., Hare\u2019e, T., Namohunu, S., Ogaoga, D., Gaiofa, J., and Usuf, E. (2022). An assessment of vaccine wastage in the Solomon Islands. PLOS Glob. Public Health, 2.","DOI":"10.1371\/journal.pgph.0000572"},{"key":"ref_15","unstructured":"(2018, May 15). World Bank Open Data. Available online: https:\/\/data.worldbank.org\/."},{"key":"ref_16","unstructured":"United Nations Department of Economic and Social Affairs (2024, September 04). World Population Prospects 2024. Available online: https:\/\/population.un.org\/wpp\/."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1412","DOI":"10.1016\/S2214-109X(22)00335-7","article-title":"Feasibility of measles and rubella vaccination programmes for disease elimination: A modelling study","volume":"10","author":"Winter","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"ref_18","unstructured":"World Bank Data Team (2024, September 05). New Country Classifications by Income Level: 2017\u20132018. 1 July 2017. Available online: https:\/\/blogs.worldbank.org\/en\/opendata\/new-country-classifications-income-level-2017-2018."},{"key":"ref_19","unstructured":"World Health Organization (2009). Measles vaccines: WHO position paper. Wkly. Epidemiol. Rec., 84, 349\u2013360."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40268-016-0144-x","article-title":"Assessing the Potential Cost-Effectiveness of Microneedle Patches in Childhood Measles Vaccination Programs: The Case for Further Research and Development","volume":"16","author":"Adhikari","year":"2016","journal-title":"Drugs R D"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e012204","DOI":"10.1136\/bmjgh-2023-012204","article-title":"Impact and cost-effectiveness of measles vaccination through microarray patches in 70 low-income and middle-income countries: Mathematical modelling and early-stage economic evaluation","volume":"8","author":"Fu","year":"2023","journal-title":"BMJ Glob. Health"},{"key":"ref_22","unstructured":"Lohmann Therapie-Systeme AG Press Release (2024, April 25). LTS to Support Micron Biomedical as Strategic CDMO Partner to Scale Up Micron\u2019s Microarray Patch Technology. 15 January 2024. Available online: https:\/\/www.ltslohmann.com\/en\/press-releases\/lts-to-support-micron-biomedical-as-strategic-cdmo-partner-to-scale-up-microns-microarray-patch-technology\/."},{"key":"ref_23","unstructured":"Nelson, M., and Vaxxas Opens Needle-Free Vax Patch Plant Down under (2024, April 25). BioProcess Insider. 20 June 2023. Available online: https:\/\/www.bioprocessintl.com\/facilities-capacity\/vaxxas-opens-needle-free-vax-patch-plant-down-under."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1007\/s13346-021-01076-4","article-title":"Manufacturing readiness assessment for evaluation of the microneedle array patch industry: An exploration of barriers to full-scale manufacturing","volume":"12","author":"Creelman","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_25","unstructured":"World Health Organization (2024, February 26). Global Measles Threat Continues to Grow as Another Year Passes with Millions of Children Unvaccinated. Available online: https:\/\/www.who.int\/news\/item\/16-11-2023-global-measles-threat-continues-to-grow-as-another-year-passes-with-millions-of-children-unvaccinated#:~:text=Of%20the%2022%20million%20children,%2C%20Nigeria%2C%20Pakistan%20and%20Philippines."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/1083\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:02:27Z","timestamp":1760112147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/12\/9\/1083"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["vaccines12091083"],"URL":"https:\/\/doi.org\/10.3390\/vaccines12091083","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]}}}